14.alpha.-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same
CA 2124382 A1 · Owner: Inoue, Satoshi · Inventors: Imaizumi, Yoshihiro; Inoue, Satoshi; Mitsunobu, Akikazu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided are stable hydrate crystals of 14.alpha.-hydroxy-4-androstene-3,6,17-trione having a biological activity of human placenta-originating estrodiene synthesis enzyme inhibitory action. These hydrate crystals include two kinds of 14.alpha.-hydroxy-4androstene-3,6,17-trione hydrate crystals having a diffraction pattern having characteristic peaks at diffraction angles in crystalline powder X-ray diffraction. Processes for producing these hydrate crystals are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 26, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 26, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 26, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.